摘要
目的探讨细胞色素P450(CYP)3A4*1G、CYP3A5*3及多药耐药(MDR1)C1236T、MDR1 G2677T/A和MDR1 C3435T基因多态性对氨氯地平降压疗效的影响。方法纳入159名原发性高血压患者,予氨氯地平5 mg·d-1干预4周,检测相关基因型,分析不同个体CYP3A4、3A5及MDR1相关基因型分布特征,考察不同单核苷酸多态性(SNP)及MDR1单倍体对氨氯地平降压疗效的影响。结果 CYP3A4*1G*1G基因型舒张压(DBP)下降幅度显著低于CYP3A4*1G*1和CYP3A4*1*1(P<0.05);CYP3A5*3*3基因型DBP下降幅度显著高于CYP3A5*1*3和CYP3A5*1*1(P<0.05);MDR1 C1236T CC、MDR1 G2677T/A AA基因型收缩压(SBP)下降幅度显著高于其他基因型(P<0.05);MDR1 C3435T各基因型治疗前后SBP、DBP下降幅度差异均无统计学意义(P>0.05)。携带MDR1 C3435T CC、MDR1 C3435T CT基因型的患者的DBP下降幅度,女性显著高于男性(P<0.05)。对MDR1单倍体分析,各组单倍体治疗前后SBP、DBP下降幅度差异均无统计学意义(P>0.05)。结论CYP3A5*3、CYP3A4*1G基因多态性可影响氨氯地平降压疗效,MDR1各单倍体未发现与氨氯地平降压疗效相关。
Objective To analyse the association of cytochrome P450 (CYP) 3A4*1G,CYP3A5*3,multidrug resistant gene (MDR1) C1236T,MDR1 G2677T/A and MDR1 C3435T gene polymorphisms on antihypertensive effect of amlodipine.Methods A total of 159 patients were screened who were assigned to receive amlodipine 5 mg · d ^-1 for 4 weeks.Antihypertensive effects were analyzed according to genotype and haploid.Results Patients with CYP3A4*1G*1G genotype had lower diastolic blood pressure ( DBP) reduction than CYP3A4*1G*1 and CYP3A4*1*1 genotype(P〈0.05).Patients with CYP3A5*3*3 gen-otype had higher DBP reduction than CYP3A5*1*3 and CYP3A5*1*1 genotype ( P 〈0.05 ).Patients with MDR1 C1236T CC, MDR1 G2677 T/A AA genotype had higher systolic blood pressure ( SBP ) re-duction than those other genotypes ( P 〈0.05 ).Female patients with MDR1 C3435T CC, MDR1 C3435T CT genotypes had higher DBP reduc-tion than male patients carried the same genotype(P〈0.05).No significant relationship was found between haploid composed by MDR1(P〈0.05).Conclusion CYP3A5*3 and CYP3A4*1 gene polymorphisms can affect antihypertensive effect to amlodipine.Female patients with MDR1 C3435 T CC and MDR1 C3435T CT genotypes had higher DBP reduction than male patients carried the same genotype, haploid com-posed by MDR1 was not found related to amlodipine antihypertensive effect.
出处
《中国临床药理学杂志》
CAS
CSCD
北大核心
2014年第11期983-987,共5页
The Chinese Journal of Clinical Pharmacology
基金
广东省科技计划基金资助项目(2011B061200025)